more information

Category:

Biologically Active Peptides

reference

1. T. Sakurai, A. Amemiya, M. Ishii, I. Matsuzaki, R.M. Chemelli, H. Tanaka, S.C. Williams, J.A. Richardson, G.P. Kozlowski, S. Wilson, J.R.S. Arch, R.E. Buckingham, A.C. Haynes, S.A. Carr, R.S. Annan, D.E. McNulty, W.-S. Liu, J.A. Terrett, N.A. Elshourbagy, D.J. Bergsma, and M. Yanagisawa, Cell, 92, 573 (1998). (Original)
2. L. de Lecea, T.S. Kilduff, C. Peyron, X.-B. Gao, P.E. Foye, P.E. Danielson, C. Fukuhara, E.L.F. Battenberg, V.T. Gautvik, F.S. Bartlett II, W.N. Frankel, A.N. van den Pol, F.E. Bloom, K.M. Gautvik, and J.G. Sutcliffe, Proc. Natl. Acad. Sci. USA, 95, 322 (1998). (cDNA; SAme Sequence [Hypocretin])
3. N. Takahashi, T. Okumura, H. Yamada, and Y. Kohgo, Biochem. Biophys. Res. Commun., 254, 623 (1999). (Pharmacol.)
4. M.S. Mondal, M. Nakazato, Y. Date, N. Murakami, M. Yanagisawa, and S. Matsukura, Biochem. Biophys. Res. Commun., 256, 495 (1999). (Distribution)
5. T. Sakurai, Regul. Pept., 85, 25 (1999). (Review)
6. J.M. Siegel, Cell, 98, 409 (1999). (Review)
7. L. De Lecea and J.G. Sutcliffe, Cell. Mol. Life Sci., 56, 473 (1999). (Review)
8. R.J. Rodgers, Y. Ishii, J.C.G. Halford, and J.E. Blundell,, Neuropeptides, 36, 303 (2002). (Review)
9. N. Tsujino and T. Sakurai, Pharmacol. Rev., 61, 162 (2009). (Review)
10. M. Mieda and T. Sakurai, CNS Neurol. Disord. Drug Targets, 8, 281 (2009). (Review)